|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
National Comprehensive Cancer Network, .
Clinical Practice Guidelines in Oncology; Colon cancer version
2.2018. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdfMay
2–2018
|
|
3
|
Labianca R, Nordlinger B, Beretta GD,
Mosconi S, Mandalà M, Cervantes A and Arnold D; ESMO Guidelines
Working Group, : Early colon cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
24:vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watanabe T, Muro K, Ajioka Y, Hashiguchi
Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S,
et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2016 for the treatment of colorectal cancer. Int J Clin
Oncol. 23:1–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Erstad DJ, Tumusiime G and Cusack JC Jr:
Prognostic and predictive biomarkers in colorectal cancer:
Implications for the clinical surgeon. Ann Surg Oncol.
22:3433–3450. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kalari S and Pfeifer GP: Identification of
driver and passenger DNA methylation in cancer by epigenomic
analysis. Adv Genet. 70:277–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wozney JM, Rosen V, Celeste AJ, Mitsock
LM, Whitters MJ, Kriz RW, Hewick RM and Wang EA: Novel regulators
of bone formation: molecular clones and activities. Science.
242:1528–1534. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hardwick JC, Van Den Brink GR, Bleuming
SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, Van
Deventer SJ and Peppelenbosch MP: Bone morphogenetic protein 2 is
expressed by, and acts upon, mature epithelial cells in the colon.
Gastroenterology. 126:111–121. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Ge Y, Sun L, Cao J, Wu Q, Guo L
and Wang Z: Effect of bone morphogenetic protein-2 on proliferation
and apoptosis of gastric cancer cells. Int J Med Sci. 9:184–192.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davis H, Raja E, Miyazono K, Tsubakihara Y
and Moustakas A: Mechanisms of action of bone morphogenetic
proteins in cancer. Cytokine Growth Factor Rev. 27:81–92. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Chen X, Qiao M, Zhang BQ, Wang N,
Zhang Z, Liao Z, Zeng L, Deng Y, Deng F, et al: Bone morphogenetic
protein 2 inhibits the proliferation and growth of human colorectal
cancer cells. Oncol Rep. 32:1013–1020. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khamas A, Ishikawa T, Shimokawa K, Mogushi
K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara
K: Screening for epigenetically masked genes in colorectal cancer
Using 5-Aza-2′-deoxycytidine, microarray and gene expression
profile. Cancer Genomics Proteomics. 9:67–75. 2012.PubMed/NCBI
|
|
14
|
Iwata N, Ishikawa T, Okazaki S, Mogushi K,
Baba H, Ishiguro M, Kobayashi H, Tanaka H, Kawano T, Sugihara K and
Uetake H: Clinical significance of methylation and reduced
expression of the quaking gene in colorectal cancer. Anticancer
Res. 37:489–498. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen XZ, Akiyama Y, Baylin SB and Yuasa Y:
Frequent epigenetic silencing of the bone morphogenetic protein 2
gene through methylation in gastric carcinomas. Oncogene.
25:2666–2673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee GH, Malietzis G, Askari A, Bernardo D,
Al-Hassi HO and Clark SK: Is right-sided colon cancer different to
left-sided colorectal cancer? -a systematic review. Eur J Surg
Oncol. 41:300–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian H, Zhao J, Brochmann EJ, Wang JC and
Murray SS: Bone morphogenetic protein-2 and tumor growth: Diverse
effects and possibilities for therapy. Cytokine Growth Factor Rev.
34:73–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miyazono K, Kamiya Y and Morikawa M: Bone
morphogenetic protein receptors and signal transduction. J Biochem.
147:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mitsui Y, Hirata H, Arichi N, Hiraki M,
Yasumoto H, Chang I, Fukuhara S, Yamamura S, Shahryari V, Deng G,
et al: Inactivation of bone morphogenetic protein 2 may predict
clinical outcome and poor overall survival for renal cell carcinoma
through epigenetic pathways. Oncotarget. 6:9577–9591. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brubaker KD, Corey E, Brown LG and
Vessella RL: Bone morphogenetic protein signaling in prostate
cancer cell lines. J Cell Biochem. 91:151–160. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnsen IK, Kappler R, Auernhammer CJ and
Beuschlein F: Bone morphogenetic proteins 2 and 5 are
down-regulated in adrenocortical carcinoma and modulate adrenal
cell proliferation and steroidogenesis. Cancer Res. 69:5784–5792.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vishnubalaji R, Yue S, Alfayez M, Kassem
M, Liu FF, Aldahmash A and Alajez NM: Bone morphogenetic protein 2
(BMP2) induces growth suppression and enhances chemosensitivity of
human colon cancer cells. Cancer Cell Int. 16:772016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Du M, Su XM, Zhang T and Xing YJ: Aberrant
promoter DNA methylation inhibits bone morphogenetic protein 2
expression and contributes to drug resistance in breast cancer. Mol
Med Rep. 10:1051–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kodach LL, Jacobs RJ, Voorneveld PW,
Wildenberg ME, Verspaget HW, van Wezel T, Morreau H, Hommes DW,
Peppelenbosch MP, van den Brink GR and Hardwick JC: Statins augment
the chemosensitivity of colorectal cancer cells inducing epigenetic
reprogramming and reducing colorectal cancer cell ‘stemness’ via
the bone morphogenetic protein pathway. Gut. 60:1544–1553. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen H, Yang J, Huang Q, Jiang MJ, Tan YN,
Fu JF, Zhu LZ, Fang XF and Yuan Y: Different treatment strategies
and molecular features between right-sided and left-sided colon
cancers. World J Gastroenterol. 21:6470–6478. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Natsume S, Yamaguchi T, Takao M, Iijima T,
Wakaume R, Takahashi K, Matsumoto H, Nakano D, Horiguchi SI,
Koizumi K and Miyaki M: Clinicopathological and molecular
differences between right-sided and left-sided colorectal cancer in
Japanese patients. Jpn J Clin Oncol. 48:609–618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Russo A, Bazan V, Iacopetta B, Kerr D,
Soussi T and Gebbia N; TP53-CRC Collaborative Study Group, : The
TP53 colorectal cancer international collaborative study on the
prognostic and predictive significance of p53 mutation: Influence
of tumor site, type of mutation, and adjuvant treatment. J Clin
Oncol. 23:7518–7528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kastenhuber ER and Lowe SW: Putting p53 in
context. Cell. 170:1062–1078. 2017. View Article : Google Scholar : PubMed/NCBI
|
